Search jobs 11-May-2021 NANOBIOTIX Partners With LianBio to Develop and Commercialize Potential First-in-Class Radioenhancer NBTXR3 Across Tumor Types and Therapeutic Combinations in China and Other Asian Markets
LianBio to collaborate in the development of NBTXR3, and contribute to enrollment in five future global registrational studies across several tumor types and therapeutic combinations including immunotherapy
Supports the expansion of global phase III registrational study in head and neck cancer into Greater China, with longer term strategic alignment across multiple tumor indications and therapeutic combinations
PARIS & CAMBRIDGE, Mass. & SHANGHAI & PRINCETON, N.J. (BUSINESS WIRE) $NBTX#LianBio Regulatory News:
NANOBIOTIX (Euronext : NANO – NASDAQ: NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced a partnershi
Share this article
Share this article
LEXINGTON, Mass., May 12, 2021 /PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that two abstracts for CA-4948, a novel, small molecule IRAK4 inhibitor, have been accepted for oral and poster presentation at the European Hematology Association 2021 Virtual Congress (EHA), which will be held virtually from June 9-17, 2021. The abstracts include updated data from a February data-cut for its ongoing open-label, single arm, Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). We are very pleased to report this clinical update on our first-in-class IRAK4 kinase inhibitor, CA-4948, as an anticancer agent for patients with acute myeloid leukemia and myelodysplastic syndromes for whom multiple prior lines of therapy have been unsuccessful, said James Dentzer, Presiden
Date Time
Mitochondrial enzyme found to block cell death pathway points to new cancer treatment strategy
The mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) plays an important and previously unknown role in blocking a form of cell death called ferroptosis, according to a new study published today in Nature by researchers at The University of Texas MD Anderson Cancer Center. Preclinical findings suggest that targeting DHODH can restore ferroptosis-driven cell death, pointing to new therapeutic strategies that may be used to induce ferroptosis and inhibit tumor growth.
“By understanding ferroptosis and how cells defend against it, we can develop therapeutic strategies to block those defense mechanisms and trigger cell death,” said senior author Boyi Gan, Ph.D., associate professor of Experimental Radiation Oncology. “We have discovered that DHODH plays a key role in defending against ferroptosis and shown that we can exploit this vulnerability with clinically tested
MD Anderson and Broad Institute Launch Translational Research Platform Focused on Rare Cancers
Share
Rare Daily Staff
The University of Texas MD Anderson Cancer Center and the Broad Institute of MIT and Harvard launched a translational research platform to study rare cancers and develop a first-of-its-kind resource for the scientific community.
The joint initiative will create a catalog of rare cancer models and provide a data resource to accelerate the identification of therapeutics to treat patients diagnosed with rare tumor types.
The National Cancer Institute defines a rare cancer as one with fewer than 40,000 new cases per year. Cumulatively, rare cancers account for roughly one-quarter of all cancer cases and cancer deaths, but the low incidence of each different type of rare tumor presents a significant challenge to efforts to identify effective therapeutic approaches.
Smith: Democrat plan on drug costs will stifle innovation
Lamar Smith, For the Express-News
May 12, 2021
FacebookTwitterEmail
This bill would be disastrous for anyone who needs prescription medicines.
The first casualties will be those who lose access to the latest lifesaving treatments for cancer and other diseases. The Democrats’ bill unwinds a carefully constructed incentive structure underpinning medical innovation, with the certain result of incalculable hardship due to the cures, treatments and vaccines that will never be developed.
Making sure Americans can afford their prescriptions is a vital national priority. But this legislation would only ensure less innovation and more Americans being deprived of new and necessary medicines. I hope my former colleagues reject this partisan exercise and work together on real solutions.